Drug intelligence / Profile preview

VIP-131I-ASON

Development stage: Preclinical
Lead developer: Sichuan University
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous

Overview

**VIP-131I-ASON** is an experimental, tumor-targeted therapeutic radiopharmaceutical consisting of a 15-mer phosphorothioate antisense oligonucleotide complementary to the translation-start region of **MYC mRNA**, radioiodinated with iodine-131 and conjugated through polylysine to vasoactive intestinal peptide. The VIP-polylysine carrier was designed to promote uptake by VIP receptor-positive tumor cells, while the antisense oligonucleotide suppresses MYC expression and the iodine-131 label contributes localized radiation-mediated cytotoxicity. In athymic mice bearing HT29 human colon adenocarcinoma xenografts, the construct increased tumor uptake relative to unconjugated radioiodinated antisense oligonucleotide and produced tumor-growth delay.

Other names: VIP-131I-ASONVIP131I-ASONVIP 131I-ASON

Targets

VIPR2 (Vasoactive intestinal polypeptide receptor 2)VIPR1 (Vasoactive intestinal peptide receptor 1)MYC (MYC proto-oncogene protein)

Beyond the preview

Go deeper on VIP-131I-ASON.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIP-131I-ASON.

Explore the full profile